Latest & greatest articles for irritable bowel syndrome

The Trip Database is a leading resource to help health professionals find trustworthy answers to their clinical questions. Users can access the latest research evidence and guidance to answer their clinical questions. We have a large collection of systematic reviews, clinical guidelines, regulatory guidance, clinical trials and many other forms of evidence. If you wanted the latest trusted evidence on irritable bowel syndrome or other clinical topics then use Trip today.

This page lists the very latest high quality evidence on irritable bowel syndrome and also the most popular articles. Popularity measured by the number of times the articles have been clicked on by fellow users in the last twelve months.

What is Trip?

Trip is a clinical search engine designed to allow users to quickly and easily find and use high-quality research evidence to support their practice and/or care.

Trip has been online since 1997 and in that time has developed into the internet’s premier source of evidence-based content. Our motto is ‘Find evidence fast’ and this is something we aim to deliver for every single search.

As well as research evidence we also allow clinicians to search across other content types including images, videos, patient information leaflets, educational courses and news.

For further information on Trip click on any of the questions/sections on the left-hand side of this page. But if you still have questions please contact us via jon.brassey@tripdatabase.com

Top results for irritable bowel syndrome

1. But I am not Depressed: Antidepressants for Irritable Bowel Syndrome

But I am not Depressed: Antidepressants for Irritable Bowel Syndrome Tools for Practice is proudly sponsored by the Alberta College of Family Physicians (ACFP). ACFP is a provincial, professional voluntary organization, representing more than 4,800 family physicians, family medicine residents, and medical students in Alberta. Established over sixty years ago, the ACFP strives for excellence in family practice through advocacy, continuing medical education and primary care research. www.acfp.ca (...) January 20, 2020 But I am not Depressed: Antidepressants for Irritable Bowel Syndrome Clinical Question: Do antidepressant medications improve irritable bowel syndrome (IBS) symptoms? Bottom Line: Both tricyclic antidepressants (TCAs) and selective serotonin reuptake inhibitors (SSRIs) may improve overall IBS symptoms. About 55% of patients treated with TCAs or SSRIs will benefit compared to ~35% with placebo. Only TCAs improve abdominal pain for ~60% of patients compared to ~30% with placebo. TCA

2020 Tools for Practice

2. Efficacy of faecal microbiota transplantation for patients with irritable bowel syndrome in a randomised, double-blind, placebo-controlled study Full Text available with Trip Pro

Efficacy of faecal microbiota transplantation for patients with irritable bowel syndrome in a randomised, double-blind, placebo-controlled study Efficacy of Faecal Microbiota Transplantation for Patients With Irritable Bowel Syndrome in a Randomised, Double-Blind, Placebo-Controlled Study - PubMed This site needs JavaScript to work properly. Please enable it to take advantage of the complete set of features! Welcome to the new PubMed. For legacy PubMed go to . Clipboard, Search History (...) be less than 100 characters Choose a collection: Unable to load your collection due to an error Add Cancel Add to My Bibliography My Bibliography Unable to load your delegates due to an error Add Cancel Actions Cite Share Permalink Copy Page navigation Gut Actions 2019 Dec 18 [Online ahead of print] Efficacy of Faecal Microbiota Transplantation for Patients With Irritable Bowel Syndrome in a Randomised, Double-Blind, Placebo-Controlled Study , , , , Affiliations Expand Affiliations 1 Stord Hospital

2020 EvidenceUpdates

3. Efficacy of psychological therapies for irritable bowel syndrome: systematic review and network meta-analysis

Efficacy of psychological therapies for irritable bowel syndrome: systematic review and network meta-analysis Print | PDF PROSPERO This information has been provided by the named contact for this review. CRD has accepted this information in good faith and registered the review in PROSPERO. The registrant confirms that the information supplied for this submission is accurate and complete. CRD bears no responsibility or liability for the content of this registration record, any associated files

2020 PROSPERO

4. [Effect of healthy eating before intervention with a low FODMAP diet in pediatric patients with irritable bowel syndrome]. Full Text available with Trip Pro

[Effect of healthy eating before intervention with a low FODMAP diet in pediatric patients with irritable bowel syndrome]. Background: a diet low in fermentable oligosaccharides, disaccharides, monosaccharides and polyols (FODMAP) may be effective in the treatment of pediatric patients with irritable bowel syndrome (IBS). Its complexity and side effects make it a secondary therapeutic alternative. Objective: to demonstrate that nutritional education, aimed at optimizing the diet of children

2019 Nutricion hospitalaria Controlled trial quality: uncertain

5. Tenapanor (Ibsrela) - irritable bowel syndrome with constipation in adults

Tenapanor (Ibsrela) - irritable bowel syndrome with constipation in adults Drug Approval Package: IBSRELA U.S. Department of Health and Human Services Search FDA Submit search Drug Approval Package: IBSRELA Company: Ardelyx, Inc. Application Number: 211801 Approval Date: 09/12/2019 Persons with disabilities having problems accessing the PDF files below may call (301) 796-3634 for assistance. FDA Approval Letter and Labeling (PDF) (PDF) FDA Application Review Files (PDF) (PDF) (PDF) (PDF) (PDF

2019 FDA - Drug Approval Package

6. AGA Clinical Practice Guidelines on the Laboratory Evaluation of Functional Diarrhea and Diarrhea-Predominant Irritable Bowel Syndrome in Adults (IBS-D) Full Text available with Trip Pro

AGA Clinical Practice Guidelines on the Laboratory Evaluation of Functional Diarrhea and Diarrhea-Predominant Irritable Bowel Syndrome in Adults (IBS-D) AGA Clinical Practice Guidelines on the Laboratory Evaluation of Functional Diarrhea and Diarrhea-Predominant Irritable Bowel Syndrome in Adults (IBS-D) - Gastroenterology Email/Username: Password: Remember me Search AGA Journals Search Terms Search within Search Access provided by Volume 157, Issue 3, Pages 851–854 AGA Clinical Practice (...) Guidelines on the Laboratory Evaluation of Functional Diarrhea and Diarrhea-Predominant Irritable Bowel Syndrome in Adults (IBS-D) x Walter Smalley Affiliations Department of Medicine, Division of Gastroenterology, Vanderbilt University School of Medicine, Nashville, Tennessee Veterans Affairs Tennessee Valley Health Care System, Nashville, Tennessee 1 , 2 , x Corinna Falck-Ytter Affiliations Departments of Medicine and Gastroenterology, Case Western Reserve University, Cleveland, Ohio Veterans Affairs

2019 American Gastroenterological Association Institute

7. Lyophilized versus Frozen Fecal Microbiota Transplant for Recurrent Clostridium Difficile Infection, Inflammatory Bowel Disease, and Irritable Bowel Syndrome: A Review of Clinical Effectiveness, Cost-Effectiveness, and Guidelines

Lyophilized versus Frozen Fecal Microbiota Transplant for Recurrent Clostridium Difficile Infection, Inflammatory Bowel Disease, and Irritable Bowel Syndrome: A Review of Clinical Effectiveness, Cost-Effectiveness, and Guidelines Lyophilized versus Frozen Fecal Microbiota Transplant for Recurrent Clostridium Difficile Infection, Inflammatory Bowel Disease, and Irritable Bowel Syndrome: A Review of Clinical Effectiveness, Cost-Effectiveness, and Guidelines | CADTH.ca Find the information you (...) need Lyophilized versus Frozen Fecal Microbiota Transplant for Recurrent Clostridium Difficile Infection, Inflammatory Bowel Disease, and Irritable Bowel Syndrome: A Review of Clinical Effectiveness, Cost-Effectiveness, and Guidelines Lyophilized versus Frozen Fecal Microbiota Transplant for Recurrent Clostridium Difficile Infection, Inflammatory Bowel Disease, and Irritable Bowel Syndrome: A Review of Clinical Effectiveness, Cost-Effectiveness, and Guidelines Last updated: August 14, 2019 Project

2019 Canadian Agency for Drugs and Technologies in Health - Rapid Review

8. Homeopathy for treatment of irritable bowel syndrome. (Abstract)

Homeopathy for treatment of irritable bowel syndrome. Irritable bowel syndrome (IBS) is a common, chronic disorder that leads to decreased health-related quality of life and work productivity. A previous version of this review was not able to draw firm conclusions about the effectiveness of homeopathic treatment for IBS and recommended that further high quality RCTs were conducted to explore the clinical and cost effectiveness of homeopathic treatment for IBS. Two types of homeopathic treatment

2019 Cochrane

9. Efficacy and Safety of Eluxadoline in Patients With Irritable Bowel Syndrome With Diarrhea Who Report Inadequate Symptom Control With Loperamide: RELIEF Phase 4 Study Full Text available with Trip Pro

Efficacy and Safety of Eluxadoline in Patients With Irritable Bowel Syndrome With Diarrhea Who Report Inadequate Symptom Control With Loperamide: RELIEF Phase 4 Study Irritable bowel syndrome with diarrhea (IBS-D) is a functional gastrointestinal disorder with limited effective treatment options. We evaluated the efficacy and safety of eluxadoline in patients with IBS-D who reported inadequate symptom control with prior loperamide.Three hundred forty-six adults with IBS-D (Rome III criteria

2019 EvidenceUpdates

10. Efficacy of Fecal Microbiota Transplantation in Irritable Bowel Syndrome: A Systematic Review and Meta-Analysis (Abstract)

Efficacy of Fecal Microbiota Transplantation in Irritable Bowel Syndrome: A Systematic Review and Meta-Analysis Irritable bowel syndrome (IBS) is a common gastrointestinal condition with a heterogeneous pathophysiology. An altered gut microbiome has been identified in some IBS patients, and fecal microbiota transplantation (FMT) has been suggested to treat IBS. We performed meta-analyses and systematic review of available randomized controlled trials (RCTs) to evaluate the efficacy of FMT

2019 EvidenceUpdates

11. Management of Irritable Bowel Syndrome (IBS)

Management of Irritable Bowel Syndrome (IBS) 1 © The Author(s) 2019. Published by Oxford University Press on behalf of the Canadian Association of Gastroenterology. This is an Open Access article distributed under the terms of the Creative Commons Attribution License (http://creative- commons.org/licenses/by/4.0/), which permits unrestricted reuse, distribution, and reproduction in any medium, provided the original work is properly cited. Received: July 11, 2018; Accepted: November 4, 2018 (...) Original Article Canadian Association of Gastroenterology Clinical Practice Guideline for the Management of Irritable Bowel Syndrome (IBS) Paul Moayyedi MD 1 , Christopher N. Andrews MD 2 , Glenda MacQueen MD 3 , Christina Korownyk MD 4 , Megan Marsiglio MD 5 , Lesley Graff MD 6 , Brent Kvern MD 7 , Adriana Lazarescu MD 8 , Louis Liu MD 9 , William G. Paterson MD 10 , Sacha Sidani MD 1 , Stephen Vanner MD 10 1 Division of Gastroenterology, McMaster University, Hamilton, Ontario, Canada; 2 Division

2019 Canadian Association of Gastroenterology

12. Irritable bowel syndrome

Irritable bowel syndrome Irritable bowel syndrome - Symptoms, diagnosis and treatment | BMJ Best Practice You'll need a subscription to access all of BMJ Best Practice Search  Irritable bowel syndrome Last reviewed: February 2019 Last updated: January 2019 Summary Irritable bowel syndrome symptoms include recurrent abdominal pain or discomfort that is associated with a change in stool frequency or form. The pain or discomfort may be relieved by defecation. It is important to determine whether (...) be individualised and is dependent on the patient's predominant symptoms. Definition Irritable bowel syndrome (IBS) is a chronic condition characterised by abdominal pain associated with bowel dysfunction. The pain is often relieved by defecation and is sometimes accompanied by abdominal bloating. There are no structural abnormalities to explain the pain. IBS occurs in about 15% of the adult population. The aetiology is probably multi-factorial and evidence suggests motility, inflammatory, genetic, immune

2019 BMJ Best Practice

13. Efficacy of Secretagogues in Patients With Irritable Bowel Syndrome With Constipation: Systematic Review and Network Meta-analysis Full Text available with Trip Pro

Efficacy of Secretagogues in Patients With Irritable Bowel Syndrome With Constipation: Systematic Review and Network Meta-analysis Several secretagogues have been approved for the treatment of irritable bowel syndrome with constipation (IBS-C). However, their relative efficacy is unclear because there have been no head-to-head randomized controlled trials. We conducted a network meta-analysis to compare their efficacies in patients with IBS-C.We searched MEDLINE, EMBASE, EMBASE Classic (...) according to their P score.We identified 15 eligible randomized controlled trials of secretagogues that included 8462 patients. Linaclotide, lubiprostone, plecanatide, and tenapanor were superior to placebo for the treatment of IBS-C. Linaclotide (290 μg once daily) was ranked first in efficacy based on the end point recommended by the Food and Drug Administration for trials in IBS-C, the primary end point used in each trial, abdominal pain, and complete spontaneous bowel movements. Tenapanor (50 mg

2019 EvidenceUpdates

14. A systematic review to examine the prevalence of non-malignant gastrointestinal conditions in adults with irritable bowel syndrome

A systematic review to examine the prevalence of non-malignant gastrointestinal conditions in adults with irritable bowel syndrome Print | PDF PROSPERO This information has been provided by the named contact for this review. CRD has accepted this information in good faith and registered the review in PROSPERO. The registrant confirms that the information supplied for this submission is accurate and complete. CRD bears no responsibility or liability for the content of this registration record

2019 PROSPERO

15. Efficacy and safety of lactulose for the treatment of irritable bowel syndrome (IBS): a systematic review protocol of randomized controlled trial

Efficacy and safety of lactulose for the treatment of irritable bowel syndrome (IBS): a systematic review protocol of randomized controlled trial Print | PDF PROSPERO This information has been provided by the named contact for this review. CRD has accepted this information in good faith and registered the review in PROSPERO. The registrant confirms that the information supplied for this submission is accurate and complete. CRD bears no responsibility or liability for the content

2019 PROSPERO

16. Exploring symptom severity, psychosocial processes, and well-being in inflammatory bowel disease with comorbid irritable bowel syndrome using the common sense model

Exploring symptom severity, psychosocial processes, and well-being in inflammatory bowel disease with comorbid irritable bowel syndrome using the common sense model Print | PDF PROSPERO This information has been provided by the named contact for this review. CRD has accepted this information in good faith and registered the review in PROSPERO. The registrant confirms that the information supplied for this submission is accurate and complete. CRD bears no responsibility or liability

2019 PROSPERO

17. Chinese herbal medicine versus probiotics for irritable bowel syndrome: protocol for a systematic review and meta-analysis of randomized controlled trials

Chinese herbal medicine versus probiotics for irritable bowel syndrome: protocol for a systematic review and meta-analysis of randomized controlled trials Print | PDF PROSPERO This information has been provided by the named contact for this review. CRD has accepted this information in good faith and registered the review in PROSPERO. The registrant confirms that the information supplied for this submission is accurate and complete. CRD bears no responsibility or liability for the content

2019 PROSPERO

18. Comorbidity and association between irritable bowel syndrome and asthma: a meta-analysis

Comorbidity and association between irritable bowel syndrome and asthma: a meta-analysis Print | PDF PROSPERO This information has been provided by the named contact for this review. CRD has accepted this information in good faith and registered the review in PROSPERO. The registrant confirms that the information supplied for this submission is accurate and complete. CRD bears no responsibility or liability for the content of this registration record, any associated files or external websites

2019 PROSPERO

19. Acupoint catgut embedding for irritable bowel syndrome with diarrhea: a systematic review

Acupoint catgut embedding for irritable bowel syndrome with diarrhea: a systematic review Print | PDF PROSPERO This information has been provided by the named contact for this review. CRD has accepted this information in good faith and registered the review in PROSPERO. The registrant confirms that the information supplied for this submission is accurate and complete. CRD bears no responsibility or liability for the content of this registration record, any associated files or external websites

2019 PROSPERO

20. The effectiveness of traditional Chinese medicine on intestinal flora in patients with diarrhea-predominant irritable bowel syndrome: a systematic review and meta-analysis of randomised controlled trials

The effectiveness of traditional Chinese medicine on intestinal flora in patients with diarrhea-predominant irritable bowel syndrome: a systematic review and meta-analysis of randomised controlled trials Print | PDF PROSPERO This information has been provided by the named contact for this review. CRD has accepted this information in good faith and registered the review in PROSPERO. The registrant confirms that the information supplied for this submission is accurate and complete. CRD bears

2019 PROSPERO